secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-057689
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics reports $18.3M cash as of Q1 2024, VIRAGE enrollment on track for Q3 completion
--------------------------------------------------------------------------------

- Cash and cash equivalents $18.3M at March 31, 2024, expected to fund operations into Q1 2025.
- R&D expenses $3.5M in Q1 2024, up 16% YoY due to clinical trial costs.
- VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.
- Positive topline data from Phase 1 trial of VCN-01 in pediatric refractory retinoblastoma – study committee deemed results positive.
- Licensing discussions ongoing for SYN-020 intestinal alkaline phosphatase asset.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/0001104659-24-057689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/tm2413496d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-057689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer